Auditing IRBs: New FDA Guidance for IRB Compliance Status
Wednesday, August 7, 2013 from 10:00 AM to 11:00 AM (PDT)
This IRB audit training will discuss the common deficiencies identified during FDA audits of IRBs, and potential solutions with case studies.
Why Should You Attend:
In the last few years, FDA found some IRBs to be highly deficient in compliance leading to Warning Letters and even closure of a few. A deficient IRB not only delays a clinical trial progress but if found during the conduct or after a trial is over could lead to major losses in data, time and cost, not to mention the loss in credibility of the sponsor with the FDA for not assuring compliance of all parties involved in their clinical trials. Recently FDA released a new guidance document describing its expectation from IRBs.
This course will list the criteria for evaluating the compliance status of the IRB supervising your clinical trial sites based on FDA’s latest guidance document. We will discuss current regulations and guidance documents governing IRB responsibilities, roles, common FDA concerns, and acceptable solutions. The presenter will use a case-study approach to explain common compliance deficiencies and solutions for addressing them.
Areas Covered in the Webinar:
- Current FDA regulations regarding IRBs.
- FDA’s audit history of IRBs with key findings.
- The latest guidance documents from FDA regarding IRBs.
- Importance of IRB registration with FDA and independent certification.
- FDA and Sponsor’s expectations from an IRB.
- Acceptable IRB functions, documentations and review fees.
- Audits by an IRB of a clinical investigator.
- Audits of IRB functions by sponsors
- Processes for creating an IRB
At ComplianceOnline, we are focused on :
- Enhancing global compliance, creating a world where quality and compliance professionals, regulators, and government agencies come together to help the world comply with the intent and the spirit of laws, policies and mandates, ensuring continuous improvement in global operations, quality & safety.
- Making sure that we are responsible corporate citizens helping our constituents build a more responsible enterprise, one which operates with high quality , under a code of ethics, and with process discipline to ensure greater shareholder returns.
- Keeping things simple and straight forward , so that we all can indeed improve the quality of our processes, our work, our businesses and enhance compliance globally.
- Being inclusive, giving the process experts ( & novices! ), compliance professionals, quality champions, and regulatory agencies a voice so that all of us can contribute and make a difference.